Aardvark Therapeutics, Inc. (AARD) stock

AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30

$1.33−0.19 (-12.50%)

Close on Nov 13, 2026Market cap $29.11MP/E –Yield –

Aardvark Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Aardvark Therapeutics's total assets was $64.80M at Sep 30, 2026. For fiscal 2025 it was $117.18M, up 51.2% from the year before.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$117.18M	+51.2%
FY2024	Dec 31, 2024	$77.51M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$64.80M	-51.4%
Q2 FY2026	Jun 30, 2026	$81.46M	-44.8%
Q1 FY2026	Mar 31, 2026	$98.59M	-37.2%
Q4 FY2025	Dec 31, 2025	$117.18M	+51.2%
Q3 FY2025	Sep 30, 2025	$133.23M	–
Q2 FY2025	Jun 30, 2025	$147.48M	–
Q1 FY2025	Mar 31, 2025	$157.03M	–
Q4 FY2024	Dec 31, 2024	$77.51M	–

Parsed from the XBRL in Aardvark Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AARD.

Advertisement
300 × 250

See a number that looks wrong?